Yaxiao Lu

Yaxiao Lu

Auto-generated profile, based on publicly available information

Yaxiao Lu

National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine and Department of Lymphoma, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. 1

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2024 in Cancer Research
Verified
Journal Article
Closed access
PDF file
XXXiyue Xu
Xiyue Xu
YZYidan Zhang
Yidan Zhang
YLYaxiao Lu
Yaxiao Lu
XZXiaoyan Zhang
Xiaoyan Zhang
CZCuicui Zhao
Cuicui Zhao
XWXianhuo Wang
Xianhuo Wang
Recurrent abnormalities in immune surveillance–related genes affect the progression of diffuse large B-cell lymphoma (DLBCL) and modulate the response to therapeutic interventions. CD58 interacts with the CD2 receptor on T cells and NK cells and is recurrently mutated and deleted in DLBCL, suggesting that it may play a role in regulating antitumor immunity. In this study, we comprehensively analyzed the genomic characteristics of CD58 through targeted next-generation sequencing, RNA sequencing (RNA-seq), whole-exome sequencing, and single-cell RNA-seq in patients with newly diagnosed DLBCL. The CD58 mutation rate was 9.1%, and the copy number loss rate was 44.7% among all enrolled patients with DLBCL. Notably, CD58 genetic alterations, along with low CD58 expression, significantly correlated with reduced rates of response to R-CHOP therapy and inferior progression-free survival and overall survival. Single-cell RNA-seq revealed that CD58 expression in tumor cells was negatively correlated with CD8+ T-cell exhaustion/dysfunction status. Insufficient T-cell activation resulting from CD58 alterations could not be attributed solely to CD2 signaling. CD58 inhibited the activity of the JAK2/STAT1 pathway by activating the LYN/CD22/SH2 domain–containing phosphatase 1 (SHP1) axis, thereby limiting PDL1 and IDO expression. Elevated PDL1 and IDO expression in CD58-deficient DLBCL cells led to immune evasion and tumor-intrinsic resistance to chimeric antigen receptor T-cell therapy. Direct activation of CD58–CD2 costimulatory signaling in combination with anti-PDL1 blockade or IDO inhibitor sensitized CD58-deficient DLBCL to chimeric antigen receptor T-cell therapy. Collectively, this work identified the multiple roles of CD58 in regulating antitumor immune responses in DLBCL. Significance: Loss of CD58 mediates immune evasion and therapy resistance in diffuse large B-cell lymphoma by upregulating PDL1 and IDO through LYN/CD22/SHP1 signaling, providing potential targets and therapeutic strategies to improve patient treatment.

5 November 2021 in Blood
Verified
Journal Article
Open access
XWXianhuo Wang
Xianhuo Wang
YLYaxiao Lu
Yaxiao Lu
YFYue Fei
Yue Fei
LLLanfang Li
Lanfang Li
LQLihua Qiu
Lihua Qiu
HZHuilai Zhang
Huilai Zhang
Background: PIM1 is a somatic hypermutation gene in diffuse large B-cell lymphoma (DLBCL) and its inhibitors exhibit a great value in application in multiple types of lymphoma. Nevertheless, investigation on its genetic alterations, biological characteristics, clinical significance and response to drugs is still lacking. Methods: We integrated the genome sequencing (discovery cohort, n=162; validation cohort, n=1001) and transcriptome sequencing (discovery cohort, n=140; validation cohort, n=928) to capture more detailed insights into the potentially biological functions of PIM1 genetic alterations, and analyzed their relationship with biological characteristics and clinical value which provide a possibility for risk stratification and therapeutic exploitation for patients with DLBCL. Results: PIM1 mutations were identified in 28.4% of DLBCL patients and significantly correlated with higher IPI scores (P=0.013), disease relapse (P=0.031) and CNS and/or testis involvement (P=0.001), as well as inferior PFS (P=0.022) and OS (P=0.0022). Multivariate analysis revealed that PIM1 mutation status was an independent poor prognostic factor (HR=2.86; 95% CI, 1.40-5.84; P=0.004). The most frequent PIM1 mutation type was missense mutations (84.1%), followed by frameshift deletions and nonsense mutations. During the distribution of base substitutions, C > T base substitution was predominant mutation type (54.4%), followed by C >G transversion (29.3%). During different exons, exon 4 of PIM1 was most often mutated. PIM1 mutations significantly co-occurred with the mutations of SETD1B (P<0.001) and CD79B (P=0.001), and was mutually exclusive to the SPEN mutation (P=0.024). We also explored the relationship between PIM1 mutations and genes distributed on previously reported signaling pathways in DLBCL and uncovered that mutations in MYD88 (P<0.001) and PRDM1 (P<0.001) involved in the NF-κB pathway were significantly enriched in the patients with PIM1 mutations. Unsurprisingly, patients with PIM1 mutations exhibited higher mutation frequencies in CD79B (P=0.001) involved in BCR pathway. PIM1 mutations were involved in immunoglobulin-related immune response, complement activation, B cell mediated immunity, B cell activation, antigen binding, and cytokine activity, which contributed to the signaling pathways of tumor microenvironment (e.g. cytokine-cytokine receptor interaction, chemokine signaling pathway, IL-17 signaling pathway, TNF signaling pathway), JAK-STAT and NF-κB. By MCODE analysis, five significant modules were obtained from the protein-protein interaction (PPI) network. Finally, a PIM1 mutation-related gene signature consisting of some independent prognostic factors was developed. According to the risk score, patients with high-risk score exhibited significantly shorter OS (P=0.0016) and PFS (P<0.001). The areas under the curve (AUCs) for the predictions of 1-, 3-, and 5-year OS were respectively 0.69, 0.70, and 0.72, suggesting that the risk score based on the PIM1 mutation-related gene signature had satisfactory sensitivity and specificity. We further found that compared to patients with low-risk score, patients with high-risk score had higher sensitivity to some drugs of targeting the immune microenvironment, including TGFβ receptor inhibitors SB525334 (P<0.0001) and SB505124 (P<0.0001) and immunomodulator Lenalidomide (P=0.041), as well as NF-κB inhibitors Parthenolide (P<0.0001) and TPCA-1 (P<0.0001) and JAK inhibitors Ruxolitinib (P=0.014) and TG101348 (P=0.0053), accompanying with significantly lower IC50 values. In addition, another common chemotherapeutic drug Gemcitabine was also predicted to be more sensitive for patients with high-risk score (P=0.047). Other targeted drugs such as Aurora kinase inhibitors VX-680 (P<0.0001) and ZM-447439 (P=0.014), Bcl-2 inhibitors Obatoclax Mesylate (P=0.00036) and Navitoclax (P<0.0001), and CDK inhibitors Roscovitine (P=0.0012), AT-7519 (P=0.0033), PHA-793887 (P<0.0001) and THZ2-49 (P=0.0053) also exhibited higher drug sensitivity for patients with high-risk score. Conclusions: PIM1 mutations play a vital role in patient risk stratification and provide novel insights into therapeutic decision making for DLBCL patients with high-risk score. Figure 1 Figure 1. Disclosures: No relevant conflicts of interest to declare.


14 May 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
YLYaxiao Lu
Yaxiao Lu
FTFei Teng
Fei Teng
BGBingling Guo
Bingling Guo
LZLu Zhang
Lu Zhang
JWJiesong Wang
Jiesong Wang
YLYao Liu
Yao Liu
Background: The rapid development of Bruton's tyrosine kinase (BTK) inhibitors has fundamentally reshaped the therapeutic landscape of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Over the past 13 years, the iterative emergence of second-generation highly selective covalent BTK inhibitors and next-generation non-covalent BTK inhibitors has dramatically expanded the clinical armamentarium for CLL/SLL. However, the exponential growth of clinical evidence for these novel agents has been highly fragmented, and the lack of comprehensive head-to-head randomized controlled trials (RCTs) has led to unprecedented clinical conundrums regarding optimal therapeutic sequencing and regimen selection for distinct patient subgroups.Methods: We employed an innovative, dual-pronged methodological framework to address these critical evidence gaps. First, a comprehensive bibliometric analysis was conducted using the Web of Science Core Collection database (January 1, 2012, to December 31, 2025) to decode the evolutionary trajectory, knowledge structure, and emerging research frontiers of BTK inhibitors in CLL/SLL. Subsequently, to resolve the comparative evidence gaps identified by bibliometric mapping, we performed a rigorous Bayesian network meta-analysis (NMA) integrating 14 landmark phase III RCTs sourced from PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science (January 1, 2012, to December 31, 2025). The efficacy endpoints, including progression-free survival (PFS), overall survival (OS), and objective response rate (ORR), as well as safety endpoints, were hierarchically ranked using the surface under the cumulative ranking curve (SUCRA) in both treatment-naïve (TN) and relapsed/refractory (R/R) cohorts, with pre-specified subgroup analyses for high-risk genomic populations.Results: Bibliometric mapping of 1,765 eligible publications revealed a definitive bimodal paradigm shift over the 13-year study period: research frontiers have pivoted from early mechanistic validation and clinical evaluations of first-generation covalent inhibitor ibrutinib, toward the exploration of acquired resistance mechanisms via "clonal dynamics" and the development of next-generation non-covalent inhibitor pirtobrutinib. Our Bayesian NMA further resolved the clinical uncertainties surrounding the comparative efficacy and safety of full-spectrum BTK inhibitor regimens. In the TN cohort, acalabrutinib plus obinutuzumab ranked highest for PFS (SUCRA=1.00), while the non-covalent inhibitor pirtobrutinib exhibited the most favorable performance for OS (SUCRA=0.93) with a superior tolerability profile. In the heavily pretreated R/R setting, zanubrutinib systematically outperformed other agents across PFS (SUCRA=0.92), OS (SUCRA=0.84), and ORR (SUCRA=0.93), with pirtobrutinib emerging as a robust salvage option (ranking second for PFS, SUCRA=0.84) particularly in patients with covalent BTK inhibitor resistance. Subgroup analyses further demonstrated that acalabrutinib plus obinutuzumab maintained superior PFS benefit in IGHV-unmutated high-risk populations.Conclusion: This integrated analysis combining macroscopic bibliometric mapping and microscopic Bayesian NMA provides the most comprehensive panoramic quantitative evaluation of the 13-year evolutionary landscape of BTK inhibitors in CLL/SLL to date. While second-generation covalent inhibitors such as zanubrutinib and acalabrutinib remain the cornerstone of first-line and R/R treatment for maximizing disease control, non-covalent agents represented by pirtobrutinib are reshaping the therapeutic sequencing paradigm, especially in the setting of acquired resistance to covalent BTK inhibitors. Clinical practice must transition from a "one-size-fits-all" approach to a highly personalized therapeutic strategy, with careful balancing of potent disease suppression, long-term tolerability, cardiovascular risk profiles, and genomic characteristics of individual patients.


17 June 2026
Verified
Other
Open access
XXXiyue Xu
Xiyue Xu
YZYidan Zhang
Yidan Zhang
YLYaxiao Lu
Yaxiao Lu
XZXiaoyan Zhang
Xiaoyan Zhang
CZCuicui Zhao
Cuicui Zhao
XWXianhuo Wang
Xianhuo Wang
Recurrent abnormalities in immune surveillance–related genes affect the progression of diffuse large B-cell lymphoma (DLBCL) and modulate the response to therapeutic interventions. CD58 interacts with the CD2 receptor on T cells and NK cells and is recurrently mutated and deleted in DLBCL, suggesting that it may play a role in regulating antitumor immunity. In this study, we comprehensively analyzed the genomic characteristics of CD58 through targeted next-generation sequencing, RNA sequencing (RNA-seq), whole-exome sequencing, and single-cell RNA-seq in patients with newly diagnosed DLBCL. The CD58 mutation rate was 9.1%, and the copy number loss rate was 44.7% among all enrolled patients with DLBCL. Notably, CD58 genetic alterations, along with low CD58 expression, significantly correlated with reduced rates of response to R-CHOP therapy and inferior progression-free survival and overall survival. Single-cell RNA-seq revealed that CD58 expression in tumor cells was negatively correlated with CD8+ T-cell exhaustion/dysfunction status. Insufficient T-cell activation resulting from CD58 alterations could not be attributed solely to CD2 signaling. CD58 inhibited the activity of the JAK2/STAT1 pathway by activating the LYN/CD22/SH2 domain–containing phosphatase 1 (SHP1) axis, thereby limiting PDL1 and IDO expression. Elevated PDL1 and IDO expression in CD58-deficient DLBCL cells led to immune evasion and tumor-intrinsic resistance to chimeric antigen receptor T-cell therapy. Direct activation of CD58–CD2 costimulatory signaling in combination with anti-PDL1 blockade or IDO inhibitor sensitized CD58-deficient DLBCL to chimeric antigen receptor T-cell therapy. Collectively, this work identified the multiple roles of CD58 in regulating antitumor immune responses in DLBCL.Significance:Loss of CD58 mediates immune evasion and therapy resistance in diffuse large B-cell lymphoma by upregulating PDL1 and IDO through LYN/CD22/SHP1 signaling, providing potential targets and therapeutic strategies to improve patient treatment.